3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Endocrine
1
Conditions
Neoplasm Metastasis
7
Carcinoma, Non-Small-Cell Lung
6
Triple Negative Breast Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Skin Neoplasms
3
Melanoma
3
Head and Neck Neoplasms
3
Breast Neoplasms
3
Recurrence
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Mycosis Fungoides
2
Multiple Myeloma
2
Lymphoma, T-Cell
2
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma, Follicular
2
Lymphoma, B-Cell
2
Glioblastoma
2
Colorectal Neoplasms
2
Advanced Malignancies
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Stomach Neoplasms
1
Recurrent Squamous Cell Carcinoma of Head
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Myelodysplastic Syndromes
1
Interventions
tremelimumab
3
durvalumab
3
Ipilimumab
3
pembrolizumab
2
Nivolumab
2
Carboplatin
2
poly ICLC
1
osimertinib
1
lenvatinib
1
cemiplimab
1
Vascular Endothelial Growth Factor A
1
Vaccination
1
Peptides
1
Pemetrexed
1
Paclitaxel
1
Monophenol Monooxygenase
1
Melphalan
1
Docetaxel
1
Axitinib
1
Antibodies, Bispecific
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Diabetes Mellitus, Insulin-Dependent, 12
×
cemiplimab
×
Clear all
NCT05142189
2026-04-14
LuCa-MERIT-1
BioNTech SE
Phase 1
Recruiting
320 enrolled